Gail Skowron, MD; Samuel A. Bozzette, MD; Lynette Lim, PhD; Carla B. Pettinelli, MD, PhD; Herbert H. Schaumburg, MD; Joseph Arezzo, PhD; Margaret A. Fischl, MD; William G. Powderly, MD; David J. Gocke, MD; Douglas D. Richman, MD; John C. Pottage, MD; Diana Antoniskis, MD; George F. McKinley, MD; Newton E. Hyslop, MD; Graham Ray, BSN; Gary Simon, MD, PhD; Nancy Reed, MSN, CANP; Marsha L. LoFaro, MA; Raj B. Uttamchandani, MD; Lawrence D. Gelb, MD; Steven J. Sperber, MD; Robert L. Murphy, MD; John M. Leedom, MD; Michael H. Grieco, MD; James Zachary, MD; Martin S. Hirsch, MD; Stephen A. Spector, MD; Joseph Bigley, MS; Whaijen Soo, MD, PhD; Thomas C. Merigan, MD
Skowron G, Bozzette SA, Lim L, Pettinelli CB, Schaumburg HH, Arezzo J, et al. Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine in Patients with AIDS or AIDS-Related Complex. Ann Intern Med. 1993;118:321-330. doi: 10.7326/0003-4819-118-5-199303010-00001
Download citation file:
Published: Ann Intern Med. 1993;118(5):321-330.
To determine whether alternating regimens consisting of zidovudine and 2′,3′-dideoxycytidine (ddC) reduce the toxicity and maintain or increase the antiretroviral effect associated with each drug alone.
An unblinded, randomized (phase II) clinical trial in which seven treatment regimens were compared.
Outpatient clinics of 12 AIDS Clinical Trials Units.
One hundred thirty-one patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex and serum p24 antigenemia (≥ 70 pg/mL).
Treatments included weekly or monthly alternating zidovudine (200 mg every 4 hours) and ddC (0.01 or 0.03 mg/kg body weight every 4 hours); weekly intermittent zidovudine, 200 mg every 4 hours, or ddC, 0.03 mg/kg every 4 hours; and continuous zidovudine.
Toxicity, CD4 cell counts, serum p24 antigen levels, and clinical end points. Data were analyzed for the first 48 weeks of therapy (median follow-up, 40 weeks).
Hematologic toxicity was significantly less frequent in patients who received zidovudine therapy every other week (11% to 15%) or every other month (11% to 14%) than in those who received continuous zidovudine therapy (33%) (P < 0.02). Weekly alternating therapy with zidovudine and ddC, 0.03 mg/kg, or intermittent therapy with ddC, 0.03 mg/kg, produced high rates of peripheral neuropathy (41% and 50%, respectively). Neuropathy occurred in 10% to 21% of patients in the other three alternating-therapy limbs and in 17% of patients receiving zidovudine alone (intermittently or continuously). Initial increases in CD4 cell counts were sustained in three alternating-therapy limbs, but counts returned to baseline by week 28 in the remaining limbs. The median weight gain at week 48 was significantly greater in patients treated with alternating regimens (0.9 to 3.8 kg) compared with those treated with continuous zidovudine therapy ( −0.7 kg) (P = 0.008). Patients treated with alternating regimens and those treated with continuous zidovudine had similarly sustained decreases in p24 antigen levels.
These findings suggest that alternating therapy with zidovudine and ddC reduces the toxicity associated with each drug alone while maintaining strong antiretroviral activity.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, HIV.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only